KRAS and chronic myelomonocytic leukemia: Additionally, we found evidence of NLRP3 inflammasome activation upon analyzing JMML, CMML, and AML patient samples harboring KRAS mutations, providing a stronger evidence of the participation of NLRP3 inflammasome in the disease development (49).